157 related articles for article (PubMed ID: 3116550)
1. Total androgen blockade vs orchiectomy in stage D2 prostate cancer.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Venner PM; Tewari HD
Prog Clin Biol Res; 1987; 243A():391-400. PubMed ID: 3116550
[No Abstract] [Full Text] [Related]
2. Maximal androgen blockade in prostatic cancer.
Denis L
Scand J Urol Nephrol Suppl; 1991; 138():137-44. PubMed ID: 1838427
[No Abstract] [Full Text] [Related]
3. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.
Navratil H
Prog Clin Biol Res; 1987; 243A():401-10. PubMed ID: 3116551
[No Abstract] [Full Text] [Related]
4. A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group.
Cancer Treat Res; 1992; 59():29-40. PubMed ID: 1347692
[No Abstract] [Full Text] [Related]
5. Total androgen ablation in the treatment of metastatic prostatic cancer. The Canadian Anandron Study Group.
Semin Urol; 1990 Aug; 8(3):159-65. PubMed ID: 2204980
[No Abstract] [Full Text] [Related]
6. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.
Brisset JM; Boccon-Gibod L; Botto H; Camey M; Cariou G; Duclos JM; Duval F; Gontiès D; Jorest R; Lamy L
Prog Clin Biol Res; 1987; 243A():411-22. PubMed ID: 3309973
[No Abstract] [Full Text] [Related]
7. Total androgen ablation: American experience.
Crawford ED; Nabors WL
Urol Clin North Am; 1991 Feb; 18(1):55-63. PubMed ID: 1899495
[TBL] [Abstract][Full Text] [Related]
8. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
Eastham JA; Sartor O
J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
[No Abstract] [Full Text] [Related]
9. [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].
Knönagel H; Bolle JF; Hering F; Senn E; Hodel T; Neuenschwander H; Biedermann C
Helv Chir Acta; 1989 Aug; 56(3):343-5. PubMed ID: 2681086
[TBL] [Abstract][Full Text] [Related]
10. What is an antiandrogen and what is the physiological and pharmacological rationale for combined "castration" + "antiandrogen" therapy.
Moguilewsky M; Cotard M; Proulx L; Tournemine C; Raynaud JP
Prog Clin Biol Res; 1987; 243A():315-40. PubMed ID: 3116549
[No Abstract] [Full Text] [Related]
11. Pulmonary complications of hormone treatment in prostate carcinoma.
Seigneur J; Trechot PF; Hubert J; Lamy P
Chest; 1988 May; 93(5):1106. PubMed ID: 3129240
[TBL] [Abstract][Full Text] [Related]
12. Total androgen ablation: Canadian experience.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
Urol Clin North Am; 1991 Feb; 18(1):75-82. PubMed ID: 1992574
[TBL] [Abstract][Full Text] [Related]
13. Total androgen blockade for metastatic cancer of the prostate.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM
Am J Clin Oncol; 1988; 11 Suppl 2():S187-90. PubMed ID: 3149456
[TBL] [Abstract][Full Text] [Related]
14. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
[TBL] [Abstract][Full Text] [Related]
15. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
16. Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study.
Beland G
Urology; 1991; 37(2 Suppl):25-9. PubMed ID: 1992600
[TBL] [Abstract][Full Text] [Related]
17. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.
Lancet; 2000 Apr; 355(9214):1491-8. PubMed ID: 10801170
[TBL] [Abstract][Full Text] [Related]
18. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
Janknegt RA
Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls.
Soloway MS
Am J Clin Oncol; 1988; 11 Suppl 1():S29-32. PubMed ID: 3133944
[TBL] [Abstract][Full Text] [Related]
20. Combined castration and androgen blockade therapy in prostate cancer. Conclusions.
Denis L; Mettlin C
Cancer; 1990 Sep; 66(5 Suppl):1086-9. PubMed ID: 2203520
[No Abstract] [Full Text] [Related]
[Next] [New Search]
